Analyzing Gossamer Bio (NASDAQ:GOSS) & Quantum Biopharma (NASDAQ:QNTM)

Gossamer Bio (NASDAQ:GOSS) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Profitability

This table compares Gossamer Bio and Quantum Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Quantum Biopharma	N/A	-582.23%	-184.20%

Valuation and Earnings

This table compares Gossamer Bio and Quantum Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47 million	0.82	-$170.37 million	($0.70)	-0.24
Quantum Biopharma	N/A	N/A	-$26.17 million	($5.49)	-0.56

Quantum Biopharma has lower revenue, but higher earnings than Gossamer Bio. Quantum Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Gossamer Bio and Quantum Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	3	4	0	2.22
Quantum Biopharma	1	0	0	0	1.00

Gossamer Bio currently has a consensus price target of $3.20, indicating a potential upside of 1,781.25%. Given Gossamer Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than Quantum Biopharma.

Risk and Volatility

Gossamer Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Insider & Institutional Ownership

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Gossamer Bio beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.